Visvanathan S, Wagner C, Rojas J, Kay J, Dasgupta B, Matteson EL, Mack M, Baker DG, Rahman MU. E-selectin, interleukin 18, serum amyloid A, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy. J Rheumatol 2009;36:1371–9.
Page 1373, left column, the first paragraph should read: “Among the biomarkers evaluated at baseline in terms of correlations with select baseline clinical measures, SAA levels were significantly correlated with select clinical characteristics, including CRP (r = 0.656, p < 0.001), ESR (r = 0.270, p < 0.001), and DAS28-CRP (r = 0.226, p = 0.0036).”
Page 1374, left column, the second section should read: “The baseline median levels of select clinical characteristics for ACR50 responders and nonresponders were similar for CRP (1.9 and 1.6 mg/dl, respectively), ESR (42 and 36 mm/h, respectively), SJC (11 and 9, respectively), TJC (15 and 13, respectively), DAS28-CRP score (5.85 and 5.82, respectively), and DAS28-ESR score (6.76 and 6.24, respectively).” Page 1374, bottom of the left column, the sentence should read: “In the combined golimumab plus MTX group, individual reductions from baseline in MMP-9 (at Week 4) and SAA and E-selectin (both at Weeks 4 and 16) correlated significantly with improvement in DAS28-CRP at Week 16 (Table 4A).”
Table 4A should read as given below; we regret the errors.